Using Eltrombopag/Eltrombopag: Potential Adverse Effects to Be Alert About

Eltrombopag/Eltrombopag, as a drug that increases platelet count, plays an important role in the treatment of patients with chronic ITP, severe aplastic anemia or chronic hepatitis C. However, like other drugs, eltrombopag may also cause a series of adverse effects, requiring patients to remain vigilant during use.

Hepatotoxicity is a potential risk of concern with eltrombopag. Medications can damage liver function, so doctors will regularly monitor changes in liver function through blood tests. Patients should pay close attention to physical discomfort symptoms, such as yellowing of the skin or eyes, darker urine, abdominal distension and pain, etc. These may be signs of liver damage.

In some patients, platelet counts may drop rapidly after stopping taking eltrombopag, even below pre-treatment levels. This usually occurs soon after stopping the medication and may last for about a month. A decrease in platelet count increases the risk of bleeding, so patients should pay close attention to any signs of bleeding or bruising and report them to their doctor promptly. In addition, eltrombopag may increase the risk of blood clots forming. The formation of blood clots may cause symptoms such as swelling of the limbs, pain, or difficulty breathing. If patients experience these symptoms, they should seek medical help immediately.

Vision changes are also one of the side effects to be wary of. Eltrombopag may cause the development or worsening of cataracts. Therefore, before and during treatment, doctors will recommend that patients undergo eye examinations. Common symptoms of cataracts include blurred vision and sensitivity to light. Once these symptoms occur, patients should seek medical attention immediately.

Nausea and vomiting are also common side effects of eltrombopag. To relieve these symptoms, patients can try to adjust their diet, such as reducing the intake of spicy, acidic, or fatty foods, and try drinking some warm ginger tea to relieve symptoms. If symptoms persist and are severe or interfere with normal eating, patients should seek medical attention immediately. Diarrhea is another common side effect. In order to relieve diarrhea, patients can try to adjust their diet, such as reducing the intake of high-fiber foods, increasing the proportion of light, easily digestible low-fiber foods, and ensuring adequate fluid intake to prevent dehydration.

Fatigue is also a health problem that may occur during treatment with eltrombopag. In order to reduce fatigue, patients can appropriately increase their rest time and arrange daily activities reasonably.

When using eltrombopag, patients should follow their doctor's instructions, take it on an empty stomach or with a low-calcium meal, and avoid taking it with drugs or products containing polyvalent cations. If any symptoms of discomfort occur during taking, the patient should inform the doctor immediately so that the treatment plan can be adjusted in time and the safety of the medication can be ensured.